SI1720611T1 - Diagnostic marker for cancer - Google Patents

Diagnostic marker for cancer

Info

Publication number
SI1720611T1
SI1720611T1 SI200531072T SI200531072T SI1720611T1 SI 1720611 T1 SI1720611 T1 SI 1720611T1 SI 200531072 T SI200531072 T SI 200531072T SI 200531072 T SI200531072 T SI 200531072T SI 1720611 T1 SI1720611 T1 SI 1720611T1
Authority
SI
Slovenia
Prior art keywords
cancer
activity
viii
protein
diagnostic
Prior art date
Application number
SI200531072T
Other languages
Slovenian (sl)
Inventor
Michael Cahill
Helmut Klocker
Hermann Rogatsch
Original Assignee
Proteosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteosys Ag filed Critical Proteosys Ag
Priority claimed from PCT/EP2005/001567 external-priority patent/WO2005078124A2/en
Publication of SI1720611T1 publication Critical patent/SI1720611T1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Use of the protein annexin A3 (I) as a diagnostic marker for prostatic cancer (PC), is new. Independent claims are also included for the following: (1) use of mitochondrial enoyl-coenzyme A-hydratase (III), ubiquitin-isopeptidase T (IV) and/or protein disulfide isomerase (V), serum amyloid P-component (VI), HES1 (VIII), the proteosome alpha -2 subunit (IX) or both (IV) and VI) as diagnostic markers for cancer; (2) use of nuclear chloride ion channel protein (VIII), adenine-phosphoribosyl transferase (X) and inorganic pyrophosphatase (XI) as diagnostic markers for PC; (3) use of a combination of the specified proteins as markers for cancer; (4) diagnostic kit that includes at least one substance for determining activity and/or abundance of the specified proteins; (5) use of an agent (II) that interacts with one of the specified marker proteins to modify its activity and/or abundance, to prepare a composition for treating (prostatic) cancer; and (6) screning for (II) that uses at least one of (I), (IV), (VI), (VII), 14-3-3 protein tau, (III), (VIII), (IX), (X), (XI) and/or their dervatives. ACTIVITY : Cytostatic; Osteopathic; Antiarthritic; Antiarteriosclerotic. No biological data is given. MECHANISM OF ACTION : Regulating activity and/or expression of marker proteins.
SI200531072T 2004-02-16 2005-02-16 Diagnostic marker for cancer SI1720611T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004008449 2004-02-16
DE102004038076A DE102004038076A1 (en) 2004-02-16 2004-07-29 Use of annexin A3, or other proteins, as diagnostic markers for cancer, especially of the prostate, also use of modulators of these markers for treating cancer
PCT/EP2005/001567 WO2005078124A2 (en) 2004-02-16 2005-02-16 Diagnostic marker for cancer
EP05707434A EP1720611B1 (en) 2004-02-16 2005-02-16 Diagnostic marker for cancer

Publications (1)

Publication Number Publication Date
SI1720611T1 true SI1720611T1 (en) 2010-09-30

Family

ID=34813531

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531072T SI1720611T1 (en) 2004-02-16 2005-02-16 Diagnostic marker for cancer

Country Status (9)

Country Link
CN (1) CN101027099B (en)
AT (1) ATE468158T1 (en)
DE (2) DE102004038076A1 (en)
DK (1) DK1720611T3 (en)
ES (1) ES2345392T3 (en)
HR (1) HRP20100356T1 (en)
PT (1) PT1720611E (en)
RS (1) RS51391B (en)
SI (1) SI1720611T1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101971023B (en) * 2008-04-08 2013-07-24 学校法人近畿大学 Method of discriminating bovine, thus discriminated bovine and kit for discriminating bovine
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
CN103797120B (en) * 2011-09-16 2017-04-12 上海长海医院 Prostate cancer biomarkers, therapeutic targets and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000993D0 (en) * 2000-01-18 2000-03-08 Univ Nottingham Trent Cancer associated genes and their products
DK1272617T3 (en) * 2000-04-01 2011-08-22 Onyvax Ltd Prostate cell lines and their use
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Also Published As

Publication number Publication date
CN101027099B (en) 2013-04-03
CN101027099A (en) 2007-08-29
DE102004038076A1 (en) 2005-09-01
RS51391B (en) 2011-02-28
HRP20100356T1 (en) 2010-09-30
DK1720611T3 (en) 2010-09-06
ATE468158T1 (en) 2010-06-15
DE502005009597D1 (en) 2010-07-01
ES2345392T3 (en) 2010-09-22
PT1720611E (en) 2010-08-26

Similar Documents

Publication Publication Date Title
RS49995B (en) The use of dialkyl fumarates
Rabenold et al. Scratching the surface: a critique of Lucas et al.(2013)'s conclusion that phytoliths do not abrade enamel
BRPI0411552A (en) sclerostin-specific antibodies and methods to increase bone mineralization
Lange et al. Intracellular S-glutathionyl adducts in murine lung and human bronchoepithelial cells after exposure to diisocyanatotoluene
FR2889921B1 (en) CONDITIONING AND APPLICATION ASSEMBLY COMPRISING A MAGNETIC DEVICE.
BR0312276A (en) Mammalian epo ch1-removed mimetibodies, compositions, methods and uses
DK2208784T3 (en) Cell proliferation inhibitors containing anti-glypican-3 antibody
BR0014486A (en) Pharmaceutical compositions containing stabilized liquid polypeptide
BR0315304A (en) Depot formulations for controlled release
EP1416273A4 (en) Method of selecting substance characterized by assaying ppard activating effect and drug
ATE529125T1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ACCELERATING WOUND HEALING
BRPI0412971A (en) hair stretching method
BRPI0411650A (en) polypeptide variant of factor vii (fvii) or factor viia (fviia), nucleotide sequence, expression vector, host cell, composition, use of a variant, and method for treating a mammal having a disease or disorder in which clot formation is desirable
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
BR0316923A (en) Mitoneet polypeptide of mitochondrial membranes, their modulators and methods for their use
BR0214450A (en) aromatic sulfone hydroxamic acids and their use as protease inhibitors
BR0309127A (en) Composition for cell proliferation
RS51391B (en) Diagnostic marker for cancer
DE60330180D1 (en) COSMETIC COMPOSITION CONTAINING A SIEGESBECKIA EXTRACT AND A LIPOPEPTIDE
DE69710747T2 (en) ASSAYS FOR HOMOCYSTEIN AND HOMOCYSTEINE DESULFURASE FROM PROTOCOUS TRICHOMONAS VAGINALIS
EP1343006A4 (en) Method of profiling protein
BR0209206A (en) Azithromycin hydrate clathrate with 1,2-propylene glycol, a process for its preparation and a pharmaceutical composition comprising the same
ES2152107T3 (en) USE OF SULFATED POLYSACARIDS IN THE TREATMENT OF CHRONIC WOUNDS.
BR0211697A (en) Cancer marker and its uses in cancer diagnosis
AU2001243322A1 (en) Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis